Hematology by the numbers
Where the hematology work is happening, from public trial, publication and grant records. Updated October 13, 2026.
2,943recruiting interventional trialsClinicalTrials.gov
36,084papers published in 2025OpenAlex
$1.3BNIH grants to outside institutions, fiscal year 2025 (2,582 projects)NIH RePORTER
191new NIH R01 grants in fiscal year 2025NIH RePORTER
Most published institutions
Papers in 2024–2025. KOLs cluster where the work is.
- The University of Texas MD Anderson Cancer CenterUS1,345
- InsermFrance1,151
- Harvard UniversityUS1,020
- Mayo ClinicUS956
- Dana-Farber Cancer InstituteUS903
- Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina873
- Memorial Sloan Kettering Cancer CenterUS855
- Fred Hutch Cancer CenterUS724
- Moffitt Cancer CenterUS669
- Assistance Publique – Hôpitaux de ParisFrance654
Most NIH funding
Grants in fiscal year 2025. Funded labs are building and buying.
- University of Pennsylvania60 grants$32M
- University of Michigan at Ann Arbor70 grants$29M
- Washington University59 grants$25M
- Sloan Kettering Institute for Cancer Research37 grants$25M
- Yale University38 grants$25M
- University of Florida37 grants$24M
- Fred Hutchinson Cancer Center35 grants$24M
- Public Health Institute4 grants$24M
- Boston Children's Hospital45 grants$24M
- Columbia University Health Sciences47 grants$24M
Where trials are recruiting
Recruiting interventional trials with a site in each country.
United States1,334
China1,030
France301
Spain248
Italy231
Australia202
United Kingdom195
Germany194
Phase 1: 1,003 · Phase 2: 1,419 · Phase 3: 335 (a two-phase study counts in both). 25% led by industry.
Fastest-growing research topics
Keywords on papers, 2022 to 2025. New topics bring new voices.
- CAR T-cell therapy221 → 5892.7×
- TP53 mutation326 → 6121.9×
- venetoclax664 → 1,1411.7×
- graft-versus-host disease prophylaxis296 → 4921.7×
- clonal hematopoiesis262 → 4361.7×
- intravenous iron247 → 4051.6×
Sources, as of October 13, 2026:
ClinicalTrials.gov (Recruiting interventional studies, conditions: leukemia, lymphoma, myeloma, MDS, anemias, sickle cell, thalassemia, hemophilia, thrombocytopenia); OpenAlex (Papers whose main topic is in the OpenAlex subfield Hematology); NIH RePORTER (NIH extramural grants in fiscal year 2025 in NIH's "Hematology" research category (RCDC); sub-projects, NIH in-house research and contracts excluded).
Where KOLs show up
Hematology covers blood cancers (leukemia, lymphoma, myeloma) and non-cancer blood disorders (sickle cell disease, hemophilia, the anemias), and the experts rarely overlap. Name the disease you sell into, then look in these places.
Congresses
The ASH annual meeting is the field's main stage, and EHA is its European counterpart. Transplant and cell therapy experts gather at the Tandem Meetings run by ASTCT and CIBMTR, and thrombosis and bleeding specialists at the ISTH Congress. See which organizations are going in our ASH 2026 guide.
Guidelines and trial networks
NCCN and ASH guideline panels set the standard of care. Trial leadership concentrates in NCI's cooperative groups, the Blood and Marrow Transplant Clinical Trials Network (BMT CTN), and CIBMTR, which tracks outcomes for transplant and cellular therapy.
Start from the numbers
The institutions publishing the most and winning the most NIH funding are where hematology KOLs cluster, and the fastest-growing keywords show which topics are gaining new voices. For the method, read how to find key opinion leaders, or search any field with the KOL Finder.